Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBT Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBT Margin for 11 consecutive years, with 400.72% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 57657.0% to 400.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 608.53% through Dec 2025, up 23197.0% year-over-year, with the annual reading at 608.53% for FY2025, 23197.0% up from the prior year.
  • EBT Margin for Q4 2025 was 400.72% at Intellia Therapeutics, up from 760.14% in the prior quarter.
  • The five-year high for EBT Margin was 210.85% in Q4 2021, with the low at 23881.33% in Q3 2021.
  • Average EBT Margin over 5 years is 2036.76%, with a median of 780.83% recorded in 2022.
  • The sharpest move saw EBT Margin plummeted -2375604bps in 2021, then surged 2310050bps in 2022.
  • Over 5 years, EBT Margin stood at 210.85% in 2021, then decreased by -26bps to 265.15% in 2022, then crashed by -272bps to 987.05% in 2023, then grew by 1bps to 977.29% in 2024, then skyrocketed by 59bps to 400.72% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 400.72%, 760.14%, and 720.21% for Q4 2025, Q3 2025, and Q2 2025 respectively.